Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive Opinion to Treat Hemophilia A in Adolescents and Adults

 Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive Opinion to Treat Hemophilia A in Adolescents and Adults

Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive Opinion to Treat Hemophilia A in Adolescents and Adults

Shots:

  • The positive opinion is based on largest pre-registration clinical programme assessing Esperoct (FD, IV, q4days) in 270 patients previously treated with severe hemophilia A and more than 5 years of clinical exposure  
  • The study resulted in effective routine prophylaxis in people with severe hemophilia A, efficacious in treatment and control of bleeding episodes and perioperative management, well tolerated and safe, maintained low median ABR of 1.18 when dosed at 50 IU/kg q4days
  • Esperoct (turoctocog alfa pegol, N8-GP) is a replacement therapy with an extended half-life factor VIII molecule indicated for people with prophylaxis and on-demand treatment of bleeding as well as for surgical procedures in adolescents (>=12 years of age) and adults with hemophilia A   

Click here to read full press release/ article | Ref: Novo Nordisk | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post